Market Newsdesk

November 30, 2025 2:23 pm

Sky Princess Arrives at Port Canaveral as First Royal-Class Ship to Sail from Central Florida

PR Newswire

PORT CANAVERAL, Fla., Nov. 30, 2025 /PRNewswire/ — Princess Cruises, one of the best-known names in cruising, today marked a major milestone with the arrival of the cruise line’s very first Royal-Class ship, Sky Princess, to homeport in Port Canaveral, beginning a season of Caribbean cruises from Central Florida.

Starting today and continuing through March 2026, Sky Princess will offer six- and eight-day Caribbean cruises to pristine beaches and tropical paradises, sailing roundtrip from Port Canaveral. The ship is scheduled to return next year for a second November 2026-March 2027 season – all cruises are on sale now.

Port Canaveral offers easy accessibility for guests driving, flying, or taking advantage of Princess’ exclusive Rail & Sail program with Brightline.

“Building on the success of our inaugural Caribbean season from Port Canaveral, we’re delighted to return to the Space Coast for another series of sailings,” said Jim Berra, Princess Cruises Chief Commercial Officer. “Our guests appreciate the convenience of cruising from Central Florida, and with the addition of Sky Princess, we’re pleased to offer even greater capacity and even more ways for guests to enjoy the Princess experience.”

Sky Princess itineraries can be combined into incredible 14-day voyages visiting the island paradises of Turks & Caicos, Puerto Rico, St. Thomas, Amber Cove, and much more.

“Princess Cruises is a valued partner and we’re very proud of the success they’ve had sailing from our Port,” said Port Canaveral CEO Capt. John Murray. “Sky Princess is a great addition to the lineup of cruise options from Central Florida. We look forward to delivering a high-quality guest experience for everyone sailing on this stunning new ship.”

The 3,660-guest, 141,000-ton Sky Princess elevates the distinctive, contemporary design and attractions of Princess’ renowned Royal-class ships. From award-winning cuisine and dynamic entertainment to elegantly appointed accommodations, Sky Princess delivers unforgettable experiences designed for today’s most discerning travelers.

Additional information about Princess Cruises is available through a professional travel advisor, by calling 1-800-PRINCESS (1-800-774-6237), or by visiting the company’s website at www.princess.com.

About Princess Cruises:
Princess Cruises is The Love Boat, the world’s most iconic cruise brand that delivers dream vacations to millions of guests every year in the most sought-after destinations on the largest ships that offer elite service personalization and simplicity customary of small, yacht-class ships. Well-appointed staterooms, world class dining, grand performances, award-winning casinos and entertainment, luxurious spas, imaginative experiences and boundless activities blend with exclusive Princess MedallionClass service to create meaningful connections and unforgettable moments in the most incredible settings in the world – the Caribbean, Alaska, Panama Canal, Mexican Riviera, Europe, South America, Australia/New Zealand, the South Pacific, Hawaii, Asia, Canada/New England, Antarctica, and World Cruises. Star Princess, the brand’s newest and most innovative ship, launched October 2025, and sister ship to Sun Princess, named Condé Nast Traveler Mega Ship of the Year for a second consecutive year. The company is part of Carnival Corporation & plc (NYSE/LSE:CCL; NYSE:CUK). 

View original content to download multimedia:https://www.prnewswire.com/news-releases/sky-princess-arrives-at-port-canaveral-as-first-royal-class-ship-to-sail-from-central-florida-302628627.html

SOURCE Princess Cruises

November 30, 2025 12:28 pm

Ellomay Capital Reports Publication of Financial Statements of Dorad Energy Ltd. as of and for the Three and Nine Months Ended September 30, 2025

TEL AVIV, Israel, Nov. 30, 2025 (GLOBE NEWSWIRE) — Ellomay Capital Ltd. (NYSE American; TASE: ELLO) (“Ellomay” or the “Company”), a renewable energy and power generator and developer of renewable energy and power projects in Europe, Israel and USA, today reported the publication in Israel of financial statements as of and for the three and nine months ended September 30, 2025 of Dorad Energy Ltd. (“Dorad”), in which Ellomay currently indirectly holds approximately 16.9% through its indirect 50% ownership of Ellomay Luzon Energy Infrastructures Ltd. (“Ellomay Luzon Energy”).

On November 30, 2025, Amos Luzon Entrepreneurship and Energy Group Ltd. (the “Luzon Group”), an Israeli public company that currently holds the remaining 50% of Ellomay Luzon Energy, which, in turn, holds 33.75% of Dorad, published its quarterly report in Israel based on the requirements of the Israeli Securities Law, 1968. Based on applicable regulatory requirements, the quarterly report of the Luzon Group includes the financial statements of Dorad for the same period.

The financial statements of Dorad as of and for the three and nine months ended September 30, 2025 were prepared in accordance with International Financial Reporting Standards. Ellomay will include its indirect share of these results (through its holdings in Ellomay Luzon Energy) in its financial results for this period. In an effort to provide Ellomay’s shareholders with access to Dorad’s financial results (which were published in Hebrew), Ellomay hereby provides a convenience translation of Dorad’s financial results.

Dorad Financial Highlights

Dorad’s revenues for the three months ended September 30, 2025 – approximately NIS 919.1 million.
Dorad’s operating profit for the three months ended September 30, 2025 – approximately NIS 205.8 million.

Based on the information provided by Dorad, the demand for electricity by Dorad’s customers is seasonal and is affected by, inter alia, the climate prevailing in that season. The months of the year are split into three seasons as follows: summer – June-September; winter – December-February; and intermediate (spring and autumn) – March-May and October-November. There is a higher demand for electricity during the winter and summer seasons, and the average electricity consumption is higher in these seasons than in the intermediate seasons and is even characterized by peak demands due to extreme climate conditions of heat or cold. In addition, Dorad’s revenues are affected by the change in load and time tariffs – TAOZ (an electricity tariff that varies across seasons and across the day in accordance with demand hour clusters), as, on average, TAOZ tariffs are higher in the summer season than in the intermediate and winter seasons. Therefore, the results presented for the quarter ended September 30, 2025, which include the summer months of July-September, are not indicative of full year results. In addition, due to various reasons, including the effects of the increase in the Israeli CPI impacting interest payments by Dorad on its credit facility and regulatory changes, the results included herein may not be indicative of third quarter results in the future or comparable to third quarter results in the past.

A convenience translation of the financial results for Dorad as of and for the year ended December 31, 2024 and as of and for each of the three and nine month periods ended September 30, 2025 and 2024 is included at the end of this press release. Ellomay does not undertake to separately report Dorad’s financial results in a press release in the future. Neither Ellomay nor its independent public accountants have reviewed or consulted with the Luzon Group, Ellomay Luzon Energy or Dorad with respect to the financial results included in this press release.

About Ellomay Capital Ltd.

Ellomay is an Israeli based company whose shares are registered with the NYSE American and with the Tel Aviv Stock Exchange under the trading symbol “ELLO”. Since 2009, Ellomay focuses its business in the renewable energy and power sectors in Europe, the USA and Israel.

To date, Ellomay has evaluated numerous opportunities and invested significant funds in the renewable, clean energy and natural resources industries in Israel, Italy, Spain, the Netherlands and Texas, USA, including:

Approximately 335.9 MW of operating solar power plants in Spain (including a 300 MW solar plant in owned by Talasol, which is 51% owned by the Company) and 51% of approximately 38 MW of operating solar power plants in Italy;
16.875% indirect interest in Dorad Energy Ltd., which owns and operates one of Israel’s largest private power plants with production capacity of approximately 850 MW;
Groen Gas Goor B.V., Groen Gas Oude-Tonge B.V. and Groen Gas Gelderland B.V., project companies operating anaerobic digestion plants in the Netherlands, with a green gas production capacity of approximately 3 million, 3.8 million and 9.5 million Nm3 per year, respectively;
83.333% of Ellomay Pumped Storage (2014) Ltd., which is involved in a project to construct a 156 MW pumped storage hydro power plant in the Manara Cliff, Israel;
51% of solar projects in Italy with an aggregate capacity of 160 MW that commenced construction processes;
Solar projects in Italy with an aggregate capacity of 134 MW that have reached “ready to build” status; and
Solar projects in the Dallas Metropolitan area, Texas, USA with an aggregate capacity of approximately 27 MW that are connected to the grid and additional 22 MW that are awaiting connection to the grid.

For more information about Ellomay, visit http://www.ellomay.com.

Information Relating to Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company’s management. All statements, other than statements of historical facts, included in this press release regarding the Company’s plans and objectives, expectations and assumptions of management are forward-looking statements. The use of certain words, including the words “estimate,” “project,” “intend,” “expect,” “believe” and similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the Company’s forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by the Company’s forward-looking statements, including changes in electricity prices and demand, continued war and hostilities and political and economic conditions generally in Israel, regulatory changes, the outcome of legal proceedings involving Dorad and its shareholders, the decisions of the Israeli Electricity Authority, changes in demand, technical and other disruptions in the operations of the power plant operated by Dorad, competition, changes in the supply and prices of resources required for the operation of the Dorad’s facilities and in the price of oil and electricity, changes in the Israeli CPI, changes in interest rates, seasonality, failure to obtain financing for the expansion of Dorad and other risks applicable to projects under development and construction, and other risks applicable to projects under development and construction, in addition to other risks and uncertainties associated with the Company’s and Dorad’s business that are described in greater detail in the filings the Company makes from time to time with Securities and Exchange Commission, including its Annual Report on Form 20-F. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Kalia Rubenbach (Weintraub)

CFO

Tel: +972 (3) 797-1111

Email: [email protected]


Dorad Energy Ltd.
Interim Condensed Statements of Financial Position
	September 30	September 30	December 31
	2025	2024	2024
	(Unaudited)	(Unaudited)	(Audited)
	NIS thousands	NIS thousands	NIS thousands
Assets
Cash and cash equivalents	1,074,718	531,210	846,565
Trade receivables and accrued income	426,129	497,530	185,625
Other receivables	29,843	43,413	32,400
Financial derivatives	–	1,661	–
Total current assets	1,530,690	1,073,814	1,064,590

Non-current assets
Restricted deposits	480,877	529,875	531,569
Long-term prepaid expenses	78,657	28,538	79,739
Fixed assets	2,595,943	2,953,489	2,697,592
Intangible assets	10,701	8,134	9,688
Right of use assets	52,636	54,250	54,199
Total non-current assets	3,218,814	3,574,286	3,372,787

Total assets	4,749,504	4,648,100	4,437,377

Liabilities
Current maturities of loans from banks	341,094	341,281	321,805
Current maturities of lease liabilities	5,124	4,941	4,887
Current tax liabilities	35,763	–	14,016
Trade payables	384,283	440,303	168,637
Other payables	39,862	10,914	14,971
Financial derivatives	1,793	–	–
Total current liabilities	807,919	797,439	524,316

Non-current liabilities
Loans from banks	1,650,143	1,904,195	1,750,457
Other long-term liabilities	38,756	9,827	60,987
Long-term lease liabilities	48,942	50,061	46,809
Provision for dismantling and restoration	38,039	36,204	38,102
Deferred tax liabilities, net	416,965	354,503	399,282
Liabilities for employee benefits, net	160	160	160
Total non-current liabilities	2,193,005	2,354,950	2,295,797

Equity
Share capital	11	11	11
Share premium	642,199	642,199	642,199
Capital reserve from activities with shareholders	3,748	3,748	3,748
Retained earnings	1,102,622	849,753	971,306
Total equity	1,748,580	1,495,711	1,617,264

Total liabilities and equity	4,749,504	4,648,100	4,437,377


Dorad Energy Ltd.
Interim Condensed Statements of Profit or Loss
	For the nine months ended		For the three months ended		Year ended
	September 30		September 30		December 31
	2025	2024	2025	2024	2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	NIS thousands	NIS thousands	NIS thousands	NIS thousands	NIS thousands
Revenues	2,096,391	2,366,358	919,055	1,096,456	2,863,770

Operating costs of the Power Plant:

Energy costs	348,607	483,965	168,087	193,180	574,572
Purchases of electricity and infrastructure services	1,073,708	1,073,350	418,989	505,678	1,372,618
Depreciation and amortization	168,757	183,735	65,909	68,016	106,266
Other operating costs	140,072	141,992	51,116	59,227	190,027

Total operating costs of Power Plant	1,731,144	1,883,042	704,101	826,101	2,243,483

Profit from operating the Power Plant	365,247	483,316	214,954	270,355	620,287
General and administrative expenses	25,698	25,328	9,209	8,600	23,929
Other income	15	30	15	30	58

Operating profit	339,564	458,018	205,760	261,785	596,416

Financing income	47,422	40,982	15,277	9,098	184,939
Financing expenses	216,241	166,818	67,355	63,736	193,825

Financing expenses, net	168,819	125,836	52,078	54,638	8,886

Profit before taxes on income	170,745	332,182	153,682	207,147	587,530

Taxes on income	39,429	76,408	35,305	47,664	135,203

Net Profit for the period	131,316	255,774	118,377	159,483	452,327


Dorad Energy Ltd.
Interim Condensed Statements of Changes in Shareholders’ Equity
	Share capital	Share premium	Capital reserve for activities with shareholders	Retained earnings	Total Equity
	NIS thousands	NIS thousands	NIS thousands	NIS thousands	NIS thousands
For the nine months ended September 30, 2025 (Unaudited)

Balance as at January 1, 2025 (Audited)	11	642,199	3,748	971,306	1,617,264
Net Profit for the period	–	–	–	131,316	131,316

Balance as at September 30, 2025 (Unaudited)	11	642,199	3,748	1,102,622	1,748,580

For the nine months ended September 30, 2024 (Unaudited)

Balance as at January 1, 202 4 (Audited)	11	642,199	3,748	643,979		1,289,937
Net Profit for the period	–	–	–	255,774		255,774
Dividend distributed	–	–	–	(50,000	)	(50,000	)
Balance as at September 30, 2024 (Unaudited)	11	642,199	3,748	849,753		1,495,711

For the three months ended September 30, 2025 (Unaudited)

Balance as at July 1, 2025 (Unaudited)	11	642,199	3,748	984,245	1,630,203
Net Profit for the period	–	–	–	118,377	118,377
Balance as at September 30, 2025 (Unaudited)	11	642,199	3,748	1,102,622	1,748,580

For the three months ended September 30, 2024 (Unaudited)

Balance as at July 1, 2024 (Unaudited)	11	642,199	3,748	740,270		1,386,228
Net Profit for the period	–	–	–	159,483		159,483
Dividend distributed	–	–	–	(50,000	)	(50,000	)

Balance as at September 30, 2024 (Unaudited)	11	642,199	3,748	849,753		1,495,711

Dorad Energy Ltd.

Interim Condensed Statements of Changes in Shareholders’ Equity (cont’d)

Share capital

Share premium

Capital reserve for activities with shareholders

Retained earnings

Total Equity

NIS thousands

For the year ended
December 31, 2024 (Audited)

Balance as at

January 1, 2024 (Audited)

642,199

3,748

643,979

1,289,937

Dividend distributed

–

(125,000)

Net profit for the year

–

452,327

Balance as at
December 31, 2024 (Audited)

642,199

3,748

971,306

1,617,264


Dorad Energy Ltd.
Interim Condensed Statements of Cash Flows
	For the nine months ended September 30				For the three months ended September 30				Year ended December 31
	2025		2024		2025		2024		2024
	(Unaudited)		(Unaudited)		(Unaudited)		(Unaudited)		(Audited)
	NIS thousands		NIS thousands		NIS thousands		NIS thousands		NIS thousands
Cash flows from operating activities
Net profit for the period	131,316		255,774		118,377		159,483		452,327
Adjustments:
Depreciation and amortization and fuel consumption	177,626		190,559		67,342		68,217		121,664
Taxes on income	39,429		76,408		35,305		47,664		135,203
Financing expenses, net	168,819		125,836		52,078		54,638		8,886
	385,874		392,803		154,725		170,519		265,753

Change in trade receivables	(240,504	)	(285,664	)	(132,459	)	(181,157	)	26,241
Change in other receivables	2,556		(36,467	)	5,852		7,454		(20,951)
Change in trade payables	269,285		266,099		150,256		207,978		(10,361
Change in other payables	25,285		(3,033	)	23,608		909		(3,481)
Change in other long-term liabilities	(19,059	)	(3,115	)	1,627		(999	)	(3,661)
	37,563		(62,180	)	48,884		34,185		(12,213)
Net cash flows from operating activities	554,753		586,397		321,986		364,187		705,867

Cash flows from investing activities
Proceeds (payment) for settlement of financial derivatives, net	(2,927	)	(2,653	)	(3,429	)	(1,603	)	1,548
Proceeds from insurance for damages to fixed assets	–		5,148		–		–		5,148
Proceeds from arbitration	–		–		–		–		337,905
Decrease in restricted deposits	–		17,500		–		–		17,500
Investment in fixed assets	(71,472	)	(34,782	)	(1,175	)	(2,646	)	(44,132)
Investment in intangible assets	(2,395	)	(1,974	)	(452	)	(505	)	(4,054)
Interest received	44,293		29,673		14,615		10,096		42,221
Net cash flows from (used in) investing activities	(32,501	)	12,912		9,559		5,342		356,136

Cash flows from financing activities
Repayment of lease liability	(227	)	(329	)	(114	)	(111	)	(4,984)
Repayment of loans from banks	(164,899	)	(141,966	)	–		–		(284,570)
Dividends paid	–		(67,500	)	–		(50,000	)	(142,500)
Interest paid	(53,810	)	(72,910	)	(154	)	(155	)	(129,957)
Proceeds from arbitration	–		–		–		–		127,195
Net cash flows used in financing activities	(218,936	)	(282,705	)	(268	)	(50,266	)	(434,816)

Net increase in cash and cash equivalents	303,316		316,604		331,277		319,263		627,187

Effect of exchange rate fluctuations on cash and cash equivalents	(75,163	)	(4,640	)	(15,540	)	(6,120	)	132
Cash and cash equivalents at beginning of period	846,565		219,246		758,981		218,067		219,246
Cash and cash equivalents at end of period	1,074,718		531,210		1,074,718		531,210		846,565

(a) significant non- cash activity Liability for gas agreements	–		–		–		–		56,208

November 30, 2025 12:03 pm

Philips launches Verida, world’s first detector-based spectral CT powered by breakthrough AI, to advance diagnostic precision

November 30, 2025

Philips pioneered detector-based spectral CT, which has been widely adopted in clinical routine exams across anatomies, supported by over 800 peer-reviewed publications [1]
CE-marked, 510k pending Verida CT [2] integrates AI across the imaging chain, providing superb image quality while accelerating workflow and reducing dose [3, 4]

Amsterdam, the Netherlands and Chicago, USA – At RSNA 2025, Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of Verida, the world’s first detector-based spectral CT fully powered by AI. This marks a transformative milestone in CT, with AI optimizing the entire imaging chain – lowering system noise, elevating image quality, and accelerating clinical workflow.

With over 800 global installations and supported by over 800 peer-reviewed publications, Philips’ spectral CT uses PACS-native delivery and has been fully embedded into clinical workflow. Spectral CT measures how tissues absorb different x-ray energy levels, enabling differentiation of materials that appear identical on conventional CT. Philips has pioneered detector-based spectral CT, delivering multiple spectral results from a single scan with no tradeoffs in performance or scan time.

Now, by integrating AI across the imaging chain, from acquisition to reconstruction, Philips Verida generates industry-leading, superior spectral image quality with minimal noise, in addition to high-definition conventional images. With its full AI capabilities, Verida can achieve dramatic dose reduction [5] without compromising image quality and reduce energy consumption by up to 45% [6].

“The clinical benefits of Verida will fundamentally change my approach to cardiac imaging,” said Prof. Eliseo Vañó Galván, cardiovascular radiologist, Chairman of the CT & MR Department at Hospital Nuestra. Sra. Del Rosario, Madrid, Spain. “With more comprehensive insights in every cardiac CT, I plan to make spectral imaging routine for all patients – building toward a fully spectral CT department. We evaluated many systems, including photon-counting CT, but chose Philips because it delivers the precision we need in a streamlined, easy-to-use platform. The result is greater diagnostic confidence and the potential to reduce the need for invasive angiograms – not just in cardiology, but across other clinical areas as well [7].”

Verida reconstructs 145 images per second, so entire exams automatically appear in less than 30 seconds – 2× faster than before and enabling up to 270 exams every day [8]. Building on Philips’ proprietary Spectral Precise Image technology – a deep learning AI reconstruction engine combined with advanced spectral imaging – and its third-generation Nano-panel Precise dual-layer detector with intrinsic noise reduction optimized for AI, Verida is designed to deliver faster, more dose-efficient spectral reconstructions. This enables clinicians to access rich spectral information from a single scan.

“Combining the latest advances in our proven spectral CT technology with AI, our flagship Verida CT system is designed to set a new standard in superior image quality and accelerated scans which are fully embedded in the radiology workflow, all to help clinicians detect and characterize disease earlier, reduce variability in diagnoses, and support efficient treatment pathways – in a single scan,” said Dan Xu, Business Leader of CT at Philips. “While photon-counting CT adds complexity, is yet to move from the research arena into clinical practice, Philips spectral CT has been a clinical workhorse for more than a decade and delivers comparable or better clinical outcomes, standing up to the most demanding throughput and at significantly lower total cost of ownership”.

Verida extends Philips’ software-defined CT approach, pairing AI-driven spectral precision to advance both clinical and operational outcomes. Built for high-demand environments, it streamlines workflows, reduces repeat scans, and delivers consistently sharp imaging across all care pathways.

Philips is debuting Verida at RSNA 2025, with availability in select markets beginning in 2026 [9].

[1] Data on file.
[2] CE marked and 510(k) pending. Not currently available for sale in the US.
[3] Andersen MB et al. Impact of spectral body imaging in patients suspected for occult cancer: a prospective study of 503 patients. Eur Radiol2020. doi.org/10.1007/s00330-020-06878-7
[4] Andersen MB et al. Economic impact of spectral body imaging in the diagnosis of patients suspected of occult cancer. Insights into Imaging 2021. doi.org/10.1186/s13244-021-01116-0. Results of customer testimonies are not predictive of results in other cases, where results may vary.
[5] Dose reduction assessments were performed using reference body protocol. In clinical practice, the use of Spectral Precise Image may reduce CT patient dose depending on the clinical task, patient size, and anatomical location. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task.
[6] Based on Axial Body 3D Scan with 80% dose reduction. Energy savings for system preparation is not included.
[7] Spectral CT Verida Premium up to 270 (4 CIRS config) exams a day (16 hours dual shift working day) meeting the needs of radiology departments with extended work hours and very high patient throughput.
[8] The statements of the clinician reflect independent opinion and are not intended to imply product performance prior to regulatory clearance.
[9] Pending regulatory clearance.

For further information, please contact:

Anna Hogrebe
Philips Global External Relations
Tel.: +1 416 270 6757
E-mail: [email protected]

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

November 30, 2025 11:43 am

Philips unveils BlueSeal Horizon, industry’s first helium-free 3.0T MRI platform

November 30, 2025

Major technology breakthrough combines advanced AI for clinical insights and accelerated workflow in new premium 3.0T MRI platform [1]

Amsterdam, the Netherlands, and Chicago, USA –
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today unveiled BlueSeal Horizon [1], an entirely new 3.0T MRI innovation platform that includes the industry’s first helium-free 3.0T magnet at RSNA 2025. A pivotal advance in MRI innovation, helium-free [2] 3.0T is a major scientific achievement set to have significant impact for health providers and patients.

3.0T MRI systems are the most advanced MRI magnet technology in widespread use, providing high-resolution imaging for research and the most complex clinical cases. These systems excel in capturing the most intricate workings of the body, especially the brain, blood vessels, muscles and joints. Philips has led the development of helium-free MRI since 2018, with more than 2,000 of its 1.5T BlueSeal MRI systems installed worldwide, saving more than 6 million liters of liquid helium to date [3]. The company is now bringing the same benefits to 3.0T MRI, eliminating the need for helium refills and vent pipes – reducing siting complexity, installation time, and total lifecycle risk.

“With BlueSeal Horizon we’re freeing MRI from dependence on a valuable resource the world can’t replace and bringing advanced diagnostic capabilities to people previously out of reach,” said Ioannis Panagiotelis, PhD, Business Leader, MR at Philips. “But more than that, BlueSeal Horizon is an entirely new 3.0T innovation platform that combines breakthroughs in hardware with AI-powered software, eliminating the trade-off between imaging speed and precision and improving outcomes for both practitioners and patients.”

Next-generation clinical AI on the Philips BlueSeal Horizon platform

Philips will bring next-generation clinical AI into everyday practice with the introduction of its new BlueSeal Horizon MR platform [1], simplifying workflows, enhancing diagnostic precision, and expanding access to advanced imaging. Key AI-powered innovations will include:

SmartPlanning: Expanding to include cardiac imaging, this AI-driven feature will automate time-consuming planning steps. What once required multiple manual actions can now be completed in a single click, achieving automated planning in as little as 30 seconds.

Real-time Scan Preview: Powered by NVIDIA’s accelerated computing platform and Open Models (Segment and Generate), this innovation aims to enable faster 3D image reconstruction, denoising, and artifact reduction, so radiologists can preview scans, adjust image quality and speed parameters in real time, and optimize workflow efficiency for more timely diagnosis.

SmartSpeed
Precise: Dual AI technology will enable scans up to three times faster and images up to 80% sharper [4], helping clinicians capture more detail in less time.

SmartReading: This tool will integrate cloud-based AI reading and reporting tools directly on the MR system, specifically for neurology and oncology applications.

Together, these innovations will bring advanced clinical AI to the point of care, helping radiology teams achieve faster, sharper, and more consistent imaging results, supporting confident, first-time-right diagnosis.

[1] 3.0T BlueSeal Horizon is ‘Work in Progress’ and not available in any jurisdiction. It is not for sale in the USA. Its future availability cannot be ensured.
[2] Helium-free operations. 7 liters of helium is permanently enclosed in the cryogenic circuit.
[3] The amount of liquid helium saved is a calculation compared to a previous generation magnet with 1500 liters of helium.
[4] Compared to Philips SENSE/ C-SENSE imaging SmartSpeed Precise is already available on current 3.0T systems.

For further information, please contact:

Jayme Maniatis
Philips Global External Relations
Tel. : +1 617 894 8368
E-mail: [email protected]

About Royal Philips

Attachment

BlueSeal Horizon, industry’s first helium-free 3.0T MRI platform

November 30, 2025 10:03 am

GE HealthCare builds on a century of innovation to shape the future of radiology at RSNA 2025

GE HealthCare builds on a century of innovation to shape the future of radiology at RSNA 2025

The company will showcase a wave of transformative innovations designed to address the most pressing challenges in healthcare, spanning the care journey across smart devices and drugs throughout disease states enabled by cloud and AI solutions.
GE HealthCare has invested more than $3B in R&D since 2022, delivering an innovation renaissance across disease states to advance precision care.

CHICAGO–(BUSINESS WIRE)–
At this year’s Radiological Society of North America’s (RSNA) 2025 Annual Meeting, GE HealthCare (Nasdaq: GEHC) will showcase a wave of significant innovations grounded by its legacy and deep, global commitment to advancing precision care. For more than a century, GE HealthCare has stood at the intersection of medicine and technology—helping clinicians see more, understand more, and do more for their patients. What began with some of the world’s earliest technology innovations in medical imaging has evolved into a strong, global focus to advancing precision care.

Solving industry challenges

Radiology departments worldwide are facing unprecedented pressure. In the coming years, healthcare providers are expected to encounter several critical challenges, including a shortage of qualified staff, rising demand for imaging services, rapid technological advancements, and the urgent need to improve operational efficiency across care settings.¹Amid these challenges, GE HealthCare is developing cloud-based and AI-enabled innovations aimed at helping providers and clinicians turn data into actionable insights, deliver precise diagnoses and treatment plans faster than before, and help hospitals boost their efficiency.

At RSNA 2025, GE HealthCare will showcase more than 40 technology innovations that merge state-of-the-art imaging device technology with advanced digital, computational and AI capabilities and are designed to address these challenges head-on: from AI-enabled imaging systems that are designed to reduce cognitive load and automate routine tasks, to structured reporting tools that can streamline workflows and improve data consistency.

“As we shape the future of care, our commitment remains clear: to deliver transformative technologies that empower clinicians, drive efficiencies, and help improve patient outcomes across multiple care pathways,” said Peter Arduini, CEO of GE HealthCare. “We start by listening to our customers, and work backwards from their challenges, then develop truly differentiated products and solutions to meet their needs today and into the future.”

Key products driving GE HealthCare’s innovation renaissance

GE HealthCare is delivering bold new solutions designed to elevate patient care and enhance the clinician experience. Since 2022, GE HealthCare has invested more than $3 billion in research and development, fueling a wave of innovation across equipment, radiopharmaceuticals and cloud and AI-enabled solutions. This year at RSNA, GE HealthCare will demonstrate new and recently announced innovations, including:

Photonova™ Spectra²(510(k) pending with the U.S. FDA; not available for sale): The new photon counting CT (PCCT) system with advanced AI algorithms,³ marks a major milestone in the company’s decades-long history in CT innovation. Built on GE HealthCare’s proprietary Deep Silicon detector technology, Photonova Spectra is designed to deliver remarkable spectral and spatial resolution for ultra-high-definition (UHD) imaging with wide coverage, seeking to enable fast acquisition speeds, precise visualization of anatomical structures and enhanced material separation. This system is designed to maximize the vast amounts of data provided, harnessing up to 50 times more data than conventional CT⁴to enable advanced reconstruction techniques and precise outputs with the aim of supporting enhanced clinical decision-making and smooth workflows.
Next-gen SIGNA MRI technology(510(k) pending at the U.S FDA; not available for sale):These technologies are designed to enhance precision diagnosis for clinicians. The innovations include:

SIGNA™ Bolt⁵aims to bring to market our most advanced high-field, clinical wide bore 3.0T MRI system and is seeking to combine ultra-high gradient performance, intelligent digital RF architecture, and sustainable design to deliver precision imaging, fast workflows, and seamless clinical-to-research flexibility, all with exceptionally low energy consumption and operational costs.

SIGNA™ Sprint with Freelium™⁶aims to broaden access to sustainable and equitable MRI technology. With less than 1% helium usage compared to conventional magnets, Freelium is designed to provide effortless sustainability without compromising clinical and operational efficiency.

Both are powered by SIGNA™ One⁷, an AI-powered workflow platform designed to improve the imaging experience by combining precision with simplicity.

Pristina™ Recon DL: This solution is GE HealthCare’s advanced 3D mammography reconstruction technology—the first to combine deep learning with iterative reconstruction to provide outstanding digital breast tomosynthesis (DBT) image quality at a low patient radiation dose. Pristina Recon DL is an enhancement to GE HealthCare’s Pristina Via™ system. Pristina Via with Recon DL mammography system offers high clinical confidence and efficient workflows with exceptional patient experience.

Vivid™ Pioneer: GE HealthCare’s most advanced and adaptive cardiovascular ultrasound platform. With one-click optimization, AI automation tools, simplified user interface and a lighter, compact, battery supported system, Vivid Pioneer is designed for extraordinary imaging, workflow, and comfort.

Flyrcado™ (flurpiridaz F 18) injection: FDA-approved PET MPI agent for adult patients with known or suspected coronary artery disease to evaluate myocardial ischemia and infarction; higher diagnostic efficacy versus SPECT, exercise-stress PET enabled by a longer half-life, and ready-to-use unit dose to support adoption. Flyrcado is expected to reach a substantial number of cardiac PET centers in the U.S. as adoption continues. CMS traditional pass-through status (effective Apr 1, 2025) supports access in HOPD settings. U.S. audiences only.

Definium Pace Select ET: An advanced floor-mounted digital X-ray system designed to deliver high-image quality and optimize efficiency in highly demanding environments while enhancing access and affordability. The system solves for many technologist challenges today by automating manual, repetitive steps and helping to reducing physical strain. The system leverages AI to help ensure accurate patient positioning and consistent image quality across various clinical conditions while streamlining the technologist workflow to maximize the patient experience and throughput.

GE HealthCare is at the forefront of developing advanced AI- and cloud-enabled capabilities to help improve workflow efficiency for radiologists. Key highlights this year include:

Genesis™ Radiology Workspace⁸anchored by Genesis Viewer (510(k) pending at the U.S FDA; not available for sale):⁹Software that is designed to be an ultra-fast diagnostic, zero-footprint viewer – streamlining radiology workflows and aiming to enhance patient care while being fully accessible from any location. Genesis Viewer is part of the GE HealthCare’s Genesis™ Radiology Workspace to help radiologists streamline their workflows. The next-generation solution is designed to transform radiology workflows, unify the user experience, and empower radiologists with great efficiency and precision.

100 FDA-authorized AI-enabled solutions: GE HealthCare leads the industry in artificial intelligence innovation, topping the FDA’s list for the most AI-enabled device authorizations of any medical device company this year. These solutions are helping to transform clinical workflows, supporting fast and precise decision-making, and expanding access to high-quality care.

“For more than 125 years, GE HealthCare has pioneered technologies that transform patient care. And while we celebrate our heritage, we remain focused on what lies ahead: a future where care is more personalized, connected, and intelligent than ever before,” said Roland Rott, CEO and President of Imaging at GE HealthCare. “This year at RSNA, our new innovations continue that tradition, empowering clinicians and advancing the boundaries of what’s possible in healthcare.”

A legacy rooted in discovery

GE HealthCare has been shaping the future of healthcare for more than a century. From the invention of the first x-ray tube still in use in modern day imaging equipment to today’s innovation renaissance, its led advances that redefine diagnostic imaging and how clinicians treat and care for patients. The company’s presence at every RSNA since its inception in 1914 reflects an enduring commitment to advance radiology and support the imaging community.

This year, GE HealthCare commemorates a series of transformative achievements that have shaped the landscape of medical imaging and patient care:

Sixty years of mammography: Since 1965, GE HealthCare has led mammography innovation—from developing the first dedicated X-ray machine to digital, 3D, and AI-powered technologies that enable early accurate diagnoses. This ongoing commitment to women’s health empowers clinicians and aims to improve outcomes worldwide.

Twenty-five years of PET/CT: Since introducing the world’s first commercially available PET/CT system in 2001—an innovation that would redefine diagnostic imaging and help transform patient care—GE HealthCare has expanded access and helped elevate precision medicine across care pathways. By combining functional and anatomical imaging, PET/CT has become an essential tool for clinicians, helping them detect, stage, and monitor cancer with greater accuracy and confidence.

A legacy of industry firsts: GE HealthCare’s history is marked by groundbreaking achievements, including the development of the first full body CT scanner, the commercialization of magnetic resonance imaging (MR), the introduction of the first color pocket-size handheld ultrasound, Vscan, in 2010, and Flyrcado in 2024, a first-of-its kind PET molecular imaging agent for diagnosing and assessing coronary artery disease, a significant game-changing innovation for nuclear cardiology. Each innovation is designed to set new standards for patient care and clinical excellence.

Strategic collaborations driving innovation

GE HealthCare’s commitment to advancing patient care goes beyond research and development—it’s strengthened by strategic collaborations and acquisitions that accelerate innovation. In the past year, the company has strengthened its portfolio to include:

MIM Software, which enhances GE HealthCare’s ability to provide advanced imaging analytics, visualization, and workflow solutions

Spectronic Medical, delivering innovations that aim to enhance radiation oncology planning

icometrix, which further expands GE HealthCare’s leadership in AI-enabled precision imaging, facilitating neurological disorder diagnosis and monitoring of disease progression

For more information on GE HealthCare and these innovative solutions at RSNA, visit booth 7334, explore the press kit, or theRSNA 2025 events page.

Important Safety Information and Usage of Flyrcado™ (flurpiridaz F 18) injection

Indications and Usage

FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.

Contraindications

None

Warnings and Precautions

Risk associated with exercise or pharmacologic stress: Patients evaluated with exercise or pharmacologic stress may experience serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, stroke, and seizure. Perform stress testing in the setting where cardiac resuscitation equipment and trained staff are readily available. When pharmacologic stress is selected as an alternative to exercise, perform the procedure in accordance with the pharmacologic stress agent’s prescribing information.

Radiation risks: FLYRCADO contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure to patients and health care providers. Advise patients to hydrate before and after administration and to void.

Adverse Reactions

Most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence ≥ 2%) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia.

Use in Specific Populations

Pregnancy

There are no data on use of flurpiridaz F 18 in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. If considering FLYRCADO administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from flurpiridaz F 18 and the gestational timing of exposure.

FLYRCADO contains ethanol (a maximum daily dose of 337 mg anhydrous ethanol). If considering FLYRCADO administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes associated with ethanol exposure during pregnancy.

Lactation

Temporarily discontinue breastfeeding. A lactating woman should pump and discard breastmilk for at least 8 hours after FLYRCADO administration.

Pediatric Use

Safety and effectiveness of FLYRCADO in pediatric patients have not been established.

To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800-654-0118 (option 2 then option 1) or by email at [email protected] or FDA at 800-FDA-1088 or www.fda.gov/medwatch

For full prescribing information, click here. For important safety information, please click here.

About GE HealthCare Technologies Inc.

GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient’s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.

Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

¹Elizabeth H. Dibble et al. “Workforce Shortage and Strategies for Mitigation: Results from the 2022 ACR/Radiology Business Management Association Workforce Survey.” Journal of the American College of Radiology 22, no. 5 (2025): 573–576. https://doi.org/10.1016/j.jacr.2025.01.xxx.

²Photonova Spectra is 510(k)-pending with the U.S. FDA. Not CE Marked. Not available for sale in the United States, Europe, Canada, or any other region.

³Enhanced Boundary for PCCT is 510(k)-pending with the U.S. FDA. Not CE Marked. Not available for sale in the United States, Europe, Canada, or any other region.

⁴When compared to Revolution Apex Elite.

⁵SIGNA Bolt is 510(k) pending at U.S. FDA. Not CE marked. Not available for sale.

⁶SIGNA Sprint with Freelium is a sealed configuration of SIGNA Sprint Select. SIGNA Sprint Select is 510(k) pending at U.S. FDA. Not CE marked. Not available for sale.

⁷SIGNA One is 510(k) pending with the U.S. FDA. Not CE marked. Not available for sale.

⁸Genesis Radiology Workspace consists of Genesis View, Enterprise Archive, Workflow Manager and App Orchestrator.

⁹Genesis Viewer is 510(k) Pending at the U.S. FDA; not available for sale.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251130700152/en/

Media Contact:

Catherine Carter

Senior Communications Manager

GE HealthCare

+1 414 396-1439

[email protected]

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Radiology Pharmaceutical Research Artificial Intelligence Oncology Software Medical Devices Hospitals Professional Services Data Management Science Technology Cardiology General Health Biotechnology Data Analytics Surgery Health Health Technology

MEDIA:

Logo

Posted on November 30, 2025 9:03 am
GE HealthCare unveils next-generation SIGNA MRI technology, aiming to boost efficiency, enhance patient experience, and advance sustainability

GE HealthCare unveils next-generation SIGNA MRI technology, aiming to boost efficiency, enhance patient experience, and advance sustainability

SIGNA Bolt¹, a new 3T MRI scanner, is designed with a next-gen gradient system engineered to support precision diagnostics, clinical efficiency, and advanced research capability.

SIGNA Sprint with Freelium,² a new sealed magnet MRI system, seeks to reimagine 1.5T MRI by combining a sustainable design with remarkable image quality, and operational autonomy to expand access to MR.

Both new systems, 510(k) pending at the U.S. FDA, are powered by SIGNA One³, an ecosystem of AI-driven workflow solutions designed to reduce inefficiencies and support MRI exams from plan to scan and beyond.

CHICAGO–(BUSINESS WIRE)–
GE HealthCare (Nasdaq: GEHC) today announced the 510(k) submissions to the U.S. Food and Drug Administration (FDA) seeking clearance for next-generation SIGNA™ MRI technology. Unveiled at the Radiological Society of North America’s 2025 Annual Meeting, these differentiated solutions are part of a wave of new GE HealthCare innovations aimed at tackling some of the most complex challenges in healthcare. Designed to enhance precision diagnosis for clinicians and help clinicians improve patient outcomes, the new technologies include GE HealthCare’s⁴ 1.5T MRI system, both equipped with an AI-powered workflow platform designed for end-to-end exam efficiency.

With imaging needs outpacing the radiologist workforce⁵, leading to longer wait times, burnout and delays in diagnosis, many departments are struggling to keep pace. At the same time, aging equipment and flat reimbursement rates are pushing providers to seek smarter, more sustainable solutions.

“The urgency for greater access, efficiency and precision in MRI has never been greater. We’ve listened to clinicians who are seeking smarter, more sustainable technologies to meet today’s challenges and tomorrow’s needs,” said Kelly Londy, President & CEO, MR, GE HealthCare. “With the introduction of our advanced SIGNA lineup, we’re delivering on a bold vision for MRI — one that intentionally puts smarter technology to work for clinicians and patients alike to make MRI more intuitive, more efficient, and more impactful in everyday care.”

SIGNA™ Bolt: Aiming to translate innovative discoveries and complex exams into everyday patient care

SIGNA Bolt⁶ aims to bring to market our most advanced high-field, clinical wide bore 3.0T MRI system and is seeking to combine ultra-high gradient performance, intelligent digital radio frequency (RF) architecture, and sustainable design to deliver precision imaging, fast workflows, and seamless clinical-to-research flexibility, all with exceptionally low energy consumption and operational costs.

SIGNA Bolt is designed to include:

The power needed to deliver diagnostic quality in everyday scans with outstanding gradient and RF performance for both research and clinical applications

Next-gen AI-enabled workflow of SIGNA One in combination with deep learning applications that are designed to enable accelerated examination times

Deep-learning based advanced applications that aim to enhance diagnostic capabilities

End-to-end clinical pathway solutions from planning to reporting for neurology and oncology

Advanced developer toolkits to simplify research

SIGNA™ Sprint with Freelium™: Designed to be purposefully helium-free without compromising on clinical or operational efficiency

SIGNA Sprint with Freelium⁷ aims to broaden access to sustainable and equitable MRI technology. With less than 1% helium usage⁸, Freelium is designed to provide effortless sustainability without compromising clinical and operational efficiency.

Engineered for excellence, the SIGNA Sprint with Freelium 1.5T system is designed to support remarkable image quality through exceptional homogeneity, high signal-to-noise ratio (SNR) and image clarity. Integrated with deep learning solutions, including AIR™ Recon DL and Sonic DL with wide coverage of anatomies and clinical applications, the system aims to provide consistent clarity and diagnostic confidence.

Designed with flexibility in mind, its Freelium ventless magnet is designed to allow installation virtually anywhere – from inside hospitals to remote regions, expanding access to advanced MR capabilities for more patients and communities. SIGNA Sprint with Freelium features two levels of operational autonomy to empower radiology departments: Scanning Autonomy with SIGNA One Interface, an intuitive user interface aiming to simplify scanning for all levels of technologist experience, and Autoramp with intelligent sensors designed to support automated magnet recovery and supporting system uptime without the need for a field engineer.

SIGNA ™ Sprint with Freelium is designed to include:

A design that uses less than 1% helium versus conventional designs⁹ with no additional power or cooling required

MR magnet installation virtually anywhere – from inside hospitals to remote regions that need more access to advanced MR capabilities, due to its ventless design

Exceptional homogeneity¹⁰ designed for impressive image quality and diagnostic capability

SIGNA One¹¹: Aiming to reduce inefficiencies with a new, AI-powered MRI workflow platform

A next-gen, AI-powered workflow platform that is designed to improve the imaging experience by combining precision with simplicity, SIGNA One offers five innovations at its core designed to streamline operations and elevate clinical confidence.

“We’re dedicated to making every interaction smooth, fast and patient centric by using predictive technology that boosts efficiency,” said Bryan Mock, PhD, General Manager, Global Product Segment, Premium MR, GE HealthCare. “SIGNA One technology is designed to simplify and improve the efficiency of experienced users, while aiming to shorten the learning curve for new users. Regardless of a users’ experience level, SIGNA One aims to liberate users from inefficiencies at every stage of the MR imaging process.”

SIGNA ™ One is designed to include¹²:

An intuitive user experience that may help reduce training time and aims to boost productivity while aiming to shorten the learning curve for new and less experienced users

The SIGNA One Table, designed to enhance patient comfort and simplify patient transport

Fully automated SIGNA One Camera with In-Room Console live feed, AI-enabled landmark localization and patient positioning verification, with real-time visual guidance on a touchscreen display — aiming to improve speed and accuracy of patient setup

Contactless respiratory and peripheral gating designed to capture physiological data effortlessly, regardless of patient orientation and without the need for external devices

High-resolution, In-Room Consoles empowering technologists with simple patient setup control, aiming to minimize interruptions and maximizing throughput

GE HealthCare is integrating with NVIDIA technology to enhance the performance and intelligence of its MR products by utilizing NVIDIA GPUs to accelerate the development of deep learning reconstruction models. Accelerated by NVIDIA’s RTX product line and programmed with the new SIGNA One MRI Workflow solutions and advanced deep learning tools that are designed to elevate the user and patient experience, SIGNA Bolt and SIGNA Sprint with Freelium are designed to provide powerful imaging techniques for tailored patient care.

Learn more about these and other GE HealthCare MRI technologies at GE HealthCare’s booth #7334 at RSNA’s annual meeting in Chicago through Dec. 4.

About GE HealthCare Technologies Inc.

GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient’s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.

Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

¹ SIGNA Bolt is 510(k) pending at U.S. FDA. Not CE marked. Not available for sale.

² SIGNA Sprint with Freelium is a configuration of SIGNA Sprint Select. SIGNA Sprint Select is 510(k) pending at U.S. FDA. Not CE marked. Not available for sale.

³ SIGNA One is 510(k) pending with the U.S. FDA. Not CE marked. Not available for sale.

⁴ Helium-free: Helium is permanently enclosed in the magnet.

⁵ Harvey L. Neiman Health Policy Institute, 2025.

⁶ SIGNA Bolt is 510(k) pending at U.S. FDA. Not CE marked, not available for sale.

⁷ SIGNA Sprint with Freelium is a sealed configuration of SIGNA Sprint Select, 510(k) pending at the U.S. FDA. Not CE marked, not available for sale.

⁸ Compared to conventional magnets.

⁹ Helium-free: Helium is permanently enclosed in the magnet

¹⁰ as conventional IPM magnet.

¹¹ SIGNA One represents features of SIGNA Bolt and SIGNA Sprint Select which are 510(k) pending at U.S. FDA. Not yet CE marked. Not available for sale.

¹² All features may not be included in all system configurations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251128574510/en/

GE HealthCare Media Contact:

Katie Scrivano

M +1 262-215-5281

[email protected]

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Biotechnology Hospitals Health Radiology Health Technology

MEDIA:

Logo

Posted on November 30, 2025 8:03 am
DeepHealth Unveils Next-Generation Imaging Informatics and Clinical AI Solutions at RSNA 2025, Advancing a New Standard of AI-Powered Care

Company expands portfolio of novel AI-powered clinical and operational solutions delivering proven impact at scale—empowering breakthroughs in care through imaging

CHICAGO, Nov. 30, 2025 (GLOBE NEWSWIRE) — DeepHealth, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), today unveils an expanded portfolio at RSNA 2025, introducing next-generation imaging informatics and clinical AI solutions. The company is announcing new offerings and major enhancements across its portfolio, spanning disease detection, assessment and monitoring, remote scanning, image management and interpretation, center operations and AI orchestration—all designed to transform the imaging experience and advance population health.

“We are entering an era where AI-powered imaging can drive proactive, connected and more equitable care at global scale,” said Kees Wesdorp, President and CEO of RadNet’s Digital Health Division, DeepHealth. “At DeepHealth, we harness AI in an integrated, end-to-end approach across our portfolio with the intent to improve healthcare delivery. By unifying clinical and operational intelligence into DeepHealth OS and deploying scalable infrastructure that accelerates adoption, our technology becomes a catalyst to stage shift disease, expand patient access, elevate care teams and enhance operational efficiency. This is how we advance our mission of empowering breakthroughs in care through imaging.”

At RSNA this year, DeepHealth showcases an expanded, integrated portfolio of AI-powered solutions that demonstrate real-world impact in addressing key healthcare challenges such as disconnected patient engagement, strained workforce, inconsistent clinical outcomes and technology, data and workflow fragmentation.

Unifying the Imaging Experience

DeepHealth connects siloed tools, teams, and workflows to automate and orchestrate key tasks in the end-to-end imaging experience. DeepHealth showcases these solutions at RSNA through its enterprise imaging and operations portfolio that includes:

Diagnostic Suite™
¹
— Accelerating and Automating Radiology: DeepHealth’s cloud-first enterprise image management and interpretation solutions deliver capabilities to automate and accelerate radiology at scale. New functionalities include cloud and hybrid data management with rapid migration, scalable ultra-fast streaming diagnostic viewer, AI-powered automated reporting and integrated advanced visualization, and enterprise AI orchestration in one seamless diagnostic environment. The recent acquisition of CIMAR UK brings additional advanced cloud image management and interoperability capabilities, supporting expanded deployments across the UK and Europe to accelerate AI-powered imaging, reporting and image-based screening. Components of Diagnostic Suite are actively deployed across RadNet sites and other customers, reflecting the Suite’s ability to deliver impact at scale in both outpatient and teleradiology environments.

TechLive™ — Expanding Capacity and Access: TechLive is a multimodality, vendor-agnostic remote imaging and radiology management solution. With first-of-kind 510(k) clearance, it extends expert oversight across MR, Ultrasound, CT and PET/CT to accelerate onboarding, meet diverse workforce needs and expand access to advanced imaging.² Deployment at RadNet to date has connected more than 400 scanners to TechLive, with results showing 42% fewer MR room closures, driving higher throughput and better patient and technologist experiences.² TechLive is available as a standalone solution or through an expanded collaboration with GE HealthCare for use with its ultrasound products. In addition, TechLive can be combined with Alpha RT as remote-scanning technology with staffing and training expertise to support diverse workforce and operational needs.

Operations Suite™ — Intelligent, Connected Imaging Operations: DeepHealth’s Operations Suite is an expanded, cloud-first suite of solutions that unifies scheduling, registration, billing, analytics and patient communication into a single environment. The Suite introduces new Patient Engagement solutions designed to improve communication, scheduling and adherence, along with agentic AI capabilities that enable automation to reduce administrative burden, optimize throughput and improve system-wide coordination. Operations Suite is being deployed across RadNet and other customer sites, as recently announced. Current customers leveraging DeepHealth RIS, previously eRAD RIS, will have the option to transition to Operations Suite through updated functionalities.

Advancing Population Health with Clinical AI Solutions
DeepHealth is introducing major advancements across its Population Health & Clinical AI portfolio, supported by expanded and new FDA clearances across multiple clinical areas. These innovations are designed to help stage shift disease, drive more timely and effective screening and diagnostic pathways, and expand patient access:

DeepHealth Breast Suite
— Elevating Breast Cancer Detection and Diagnosis: The new Breast Suite³ an AI-powered, FDA-cleared end-to-end suite of modular interoperable applications that significantly enhances diagnostic accuracy,⁴ improve workflow efficiency and drive greater standardization of care.⁴^,⁵ Breast Suite delivers one of the industry’s most comprehensive breast cancer detection and diagnostic offerings by including breast cancer detection, risk asssesment,⁶ breast density, workflow tools and, in development, breast arterial calcification assessment.⁷ Breast Suite builds on organic innovation and technology integrated through the acquisition of iCAD to deliver a comprehensive new suite of solutions.

Breast Suite applications already support annually more than 10 million mammograms globally.

The largest real-world analysis of AI-powered breast cancer screening in the US recently published in Nature Health demonstrated the effectiveness of applications within Breast Suite to deliver a 21% increase in breast cancer detection rate in over 579,000 women, with consistent benefits across dense-breast and diverse patient populations.⁴

DeepHealth and GE HealthCare will expand their existing collaboration to include a wider suite of AI tools and extend access to the combined offering of their mammography systems with DeepHealth Breast Suite worldwide.

DeepHealth Thyroid Suite — Transforming Thyroid Ultrasound Imaging: The Thyroid Suite,⁸ an AI-powered suite of modular applications seamlessly integrates into existing thyroid ultrasound workflows and technology, automating measurements and characterization⁹^,¹⁰ and significantly improving workflow efficiency.¹¹ By automating nodule detection, characterization and standardizing worksheets and reporting, Thyroid Suite applications help radiologists and sonographers work more efficiently and consistently. Thyroid Suite builds on organic innovation and technology integrated through the acquisition of See-Mode to deliver a new suite of solutions. Deployment across more than 200 sites within RadNet has demonstrated transformative real-world impact: radiologists interpreting more than 4,070 nodules accepted AI-based measurements and characterization without correction in greater than 94% of the cases.¹² The solution supports all ultrasound manufacturers and is available standalone or through the recently announced partnership with GE HealthCare’s ultrasound imaging.

DeepHealth Neuro Suite — Quantifying Structural Changes for Proactive Care: The Neuro Suite¹³ applications automate and standardize neuroimaging analysis. It includes the FDA-cleared applications: Brain Health for white matter hyperintensity (WMH) detection and segmentation and Brain Age for volumetric measurement. By automatically quantifying key structures — including the hippocampus, lobes and subcortical regions — Neuro Suite tracks longitudinal progression to support proactive care.

DeepHealth Chest Suite — Stage Shifting Lung Cancer: The applications of the expanded Chest Suite,¹⁴ previously referred to as DeepHealth Lung, automate pulmonary nodule detection, characterization and volumetric quantification, as well as standardize reporting and longitudinal tracking. These automations support radiologists in identifying disease earlier and improving diagnostic accuracy,¹⁵^,1⁶ Chest Suite applications continue to enable population-scale screening programs worldwide, including NHS England’s Lung Cancer Screening Program for which UK Government data show that 76% of detected cancers are now caught at earlier, more treatable stages, compared to only 29% historically.¹⁷ Applications within the Chest Suite are cleared in Europe and the UK and are currently US 510(k)-pending, with plans to expand availability to US clinical sites.

DeepHealth Prostate Suite — Advancing Diagnosis of Prostate Cancer: The next generation Prostate Suite¹⁸ streamlines prostate MRI interpretation, analysis and biopsy planning workflows. The suite integrates automated lesion detection and risk classification (510K pending), intelligent gland segmentation with PSA density calculation, and PI-RADS-compliant reporting into a single platform, delivering diagnostic accuracy¹⁹ and standardization of care.¹⁹ From initial scan review to targeted biopsy handoff, the solution connects seamlessly with 9+ fusion biopsy systems, eliminating manual data transfer while supporting radiologists at every step. The Suite supports customer programs in the US and was recently selected to support the TRANSFORM prostate screening trial in the UK.

AI Studio — Enabling a Sustainable and Responsible AI Ecosystem: AI Studio, developed in partnership with CARPL and RagaAI, unifies a range of ecosystem AI solutions and enables seamless orchestration of these applications directly within the clinical workflow for automation and AI-powered care. AI Studio can integrate 140+ AI algorithms from 75+ ecosystem vendors, along DeepHealth’s own clinical AI solutions, directly into the worklist, viewer, reporting and workflow engine. The system includes governance tools for AI evaluation, monitoring and drift management in production, ensuring consistent performance and safe, reliable deployment at scale.

At the core of this portfolio is DeepHealth OS™, a cloud-native operating system that brings together these imaging informatics and AI suites into one unified environment. The OS delivers personalized, role-based experiences with seamless access to clinical and operational data, meeting the needs of every participant in the imaging workflow. With all solutions running on one cloud-native or hybrid platform, deployment, operations, security and infrastructure management are greatly simplified for IT professionals implementing tech solutions in healthcare.

DeepHealth works with leading OEMs, cloud, AI, and platform partners to unify previously fragmented tools into a connected, end-to-end imaging experience. Elements of DeepHealth’s portfolio are already delivering meaningful impact for patients and healthcare providers around the world, with over 2,000 customers and more than 5,000 radiologists leveraging its current solutions to deliver better care.

DeepHealth’s portfolio²⁰ is presented in scientific sessions and at Booth #1329, South Hall, Level 3 at McCormick Place in Chicago. Anchoring the space will be an Experience Theater where visitors can experience interactive, hands-on educational lectures illustrating how AI is being integrated into practice across diverse clinical and operational areas. The Theater will also feature live sessions and panel discussions with clinical collaborators, technology partners and research leaders sharing insights from real-world AI deployments and upcoming technological advancements.

Explore more about DeepHealth’s presence at RSNA 2025 and view the full schedule of live Experience Theater sessions at deephealth.com/rsna.

About DeepHealth
DeepHealth is a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for RadNet’s Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in breast, chest, prostate, neuro, and thyroid health. At the heart of DeepHealth’s portfolio is a cloud-native operating system – DeepHealth OS – that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth’s human-centered, intuitive technology aims to push the boundaries of what’s possible in healthcare. https://deephealth.com

About RadNet, Inc.
 

RadNet, Inc. is a leading provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 407 owned and/or operated outpatient imaging centers. RadNet’s markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has about 11,000 team members. https://radnet.com

Forward-Looking Statements

This communication contains certain “forward-looking statements” within the meaning of the safe harbour provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as: “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “outlook,” “plan,” “potential,” “possible,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would,” the negative of these words, and similar references to future periods. Examples of forward-looking statements include statements regarding the unifying clinical and operational intelligence into one system and enabling rapid-scale infrastructure that accelerates adoption, our technology becomes a catalyst to stage shift disease, expand patient access, elevate care teams and enhance operational efficiency, discussions regarding our product feature, and statements regarding our recent acquisitions. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, many of which are beyond RadNet’s control.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations and assumptions regarding the future of RadNet’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet’s control. RadNet’s actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of various factors. Neither RadNet, nor any of its directors, executive officers, or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur, or if any of them do occur, what impact they will have on the business, results of operations or financial condition of RadNet. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on RadNet’s business and the ability to realize the expected benefits of the acquisition. Risks and uncertainties that could cause results to differ from expectations include, but are not limited to: (1) the ability to recognize the anticipated benefits of the technology, and (2) the risk of legislative, regulatory, economic, competitive, and technological changes, and other risks and uncertainties described in the “Risk Factors,” “Management’s Discussion and Analysis,” and other sections of our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in RadNet’s filings with the Securities and Exchange Commission (the “SEC”), including the risk factors discussed in RadNet’s most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q and future filings with the SEC.

Forward-looking statements included herein are made only as of the date hereof and, except as required by applicable law, RadNet does not undertake any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent. All forward-looking statements in this communication are qualified in their entirety by this cautionary statement.

DeepHealth Media Contact

Andra Axente
Director of Communications
+31614440971
[email protected]

RadNet Media Contacts
 

Jane Mazur 
SVP, Corporate Communications
+1 585-355-5978 
[email protected] 

Mark Stolper
Executive Vice President and Chief Financial Officer
+1 310-445-2800

References

Diagnostic Suite comprises multiple applications, including DeepHealth Viewer. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. Any claims made about Diagnostic Suite may reference claims associated with its individual components.

Data on file. In a pilot deployment at 64 locations inside of RadNet’s New York area facilities, TechLive™ significantly contributed to a 27% increase in advanced breast MRI as a result of using DeepHealth’s TechLive remote scanning capability across 33 MR systems at RadNet NY centers since Feb 2025.

Breast Suite comprises multiple applications including ProFound Pro, Breast Density, Safeguard Review, Risk Assessment, and DeepHealth Viewer. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. Risk Assessment is not cleared for use in the U.S. BAC is in development; regulatory submission planned prior to the end of 2025. Not cleared for use in the US. Not all products and functions are available in all markets. Any claims made about Breast Suite may reference claims associated with its individual components.

Louis, L. et al. “Equitable Impact of an AI-Driven Breast Cancer Screening Workflow in Real World US-wide Deployment.” Nature Health, 2025.

McCabe et al. “Multistage AI-Driven Workflow Improves General Radiologist Screening Mammography Performance to the Level of Fellowship-Trained Breast Imagers: Real-world Evidence in >500,000 Patients.” RSNA Chicago. 2025.

Not cleared for use in the U.S. Capability available in Europe.

In development, regulatory submission planned prior to the end of 2025. Not cleared for use in the US.

DeepHealth Thyroid Suite comprises multiple applications including DeepHealth Viewer and DeepHealth Thyroid AI. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth. DeepHealth Thyroid AI is manufactured as See-Mode Augmented Reporting Tool, Thyroid (SMART-T) by See-Mode and Distributed by DeepHealth Inc. Any claims made about Thyroid Suite may reference claims associated with its individual components.

Data on file. Summary of Performance Testing Studies, Thyroid 510(k) clearance.

Data on file. “Evaluation of AI-enhanced Thyroid Ultrasound Reporting Software for Improved Diagnostic Consistency.”

Data on file. DeepHealth’s Thyroid AI demonstrated up to a 30% reduction in scan slot time. Initial deployment at RadNet outpatient imaging centers.

Data on file. Results are based on data from 240+ RadNet sites and 22,000 thyroid studies.

Neuro Suite comprises multiple applications including Brain Health, Brain Age and DeepHealth Viewer. DeepHealth Viewer is manufactured by eRAD and distributed by DeepHealth. Any claims made about Neuro Suite may reference claims associated with its individual components. Not all products and functions are available in all markets.

Chest Suite comprises multiple applications including Veye Lung Nodules, Veye Reporting, DeepHealth Lung AI, DeepHealth Viewer and HealthCCSng. Veye Lung Nodules and Veye Reporting are manufactured by Aidence B.V. and distributed by DeepHealth, Inc. Neither Veye Lung Nodules nor Veye Reporting are FDA cleared for distribution in the US. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. in the US. HealthCCSng is manufactured by Nanox AI, Ltd. and distributed by DeepHealth, Inc. DeepHealth Lung AI is 510(k) pending. Not all products and functions are available in all markets.

Identifies solid and sub-solid nodules (3-30mm) with 91% sensitivity, 1 false positive per scan. Setio et al. “Validation, comparison, and combination of algorithms for automatic detection of pulmonary nodules….” Med Image Anal. Dec 2017.

Increases agreement (κ up to 0.82), reduces reading time up to 42%. Hempel et al. “Higher agreement between readers with deep learning CAD software for reporting pulmonary nodules o….” Eur J RadiolOpen. Aug 2022.

Mouland et al. “Targeted Lung Health Check Programme Final evaluation report.” Ipsos. November 2024.

DeepHealth Prostate Suite comprises multiple applications including Quantib Prostate, DeepHealth Prostate AI and DeepHealth Viewer. Quantib Prostate is Manufactured by Quantib BV and distributed by DeepHealth, Inc, in the US. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. DeepHealth Prostate AI is FDA 510(k) pending. Any claims made about Prostate Suite may reference claims associated with its individual components. Not all products and functions are available in all markets.

Data on file. DeepHealth pivotal study for FDA 510(k) clearance of Prostate AI, 12-reader by 250-case MRMC study and standalone testing on the same 250 exams.

Not all products and functionalities are commercially available in all countries. For clearance and commercial availability in your geography of functionalities listed and compatibility with other systems, please contact a DeepHealth representative.

Posted on November 29, 2025 1:05 pm
U.S. Retail Traffic Was In-Line With Year-to-Date Trends on Black Friday, According to Sensormatic Solutions ShopperTrak Analytics

U.S. Retail Traffic Was In-Line With Year-to-Date Trends on Black Friday, According to Sensormatic Solutions ShopperTrak Analytics

In-store traffic was down 2.1% compared to 2024 Black Friday results, on par with 2025 results year-to-date (-2.2%).

Week of Black Friday (Nov. 23-28) traffic was up 56.7% compared to the week prior (Nov. 16-21).

Shopper traffic on Black Friday (Nov. 28) exceeded the previous Friday (Nov. 21) by 248.9%.

NEUHAUSEN, Switzerland–(BUSINESS WIRE)–Sensormatic Solutions, the leading global retail solutions portfolio of Johnson Controls (NYSE: JCI), today shared its initial analysis of Black Friday in-store traffic for the 2025 U.S. holiday season. According to its ShopperTrak Analytics insights, which captures 40 billion store visits globally each year, retail visits on the annual shopping holiday were down slightly compared to 2024 (-2.1%), but shopper traffic was in-line with 2025 year-to-date (-2.2%). Compared to the previous Friday (Nov. 21), traffic on Nov. 28 was up 248.9%.

“Traffic has been steadily picking up throughout the second half of 2025, kicking off during the back-to-school season, and this week’s strong showing hints this trend is likely to continue throughout the rest of the holiday season,” said Grant Gustafson, head of retail consulting and analytics at Sensormatic Solutions. “Black Friday is still expected to be the busiest shopping day of the year as consumers prioritize leveraging peak discount days to purchase big-ticket items on their lists.”

ShopperTrak Analytics data also showed that early afternoon is still the most popular time for Black Friday browsing. As in years past, in-store traffic peaked between 2 and 4 p.m., with 3 p.m. marking the busiest hour for retailers.

The Season Ahead

Black Friday may be the predicted busiest day of the 2025 holiday shopping season in the U.S., but the retail rush is just getting started. According to Sensormatic Solutions predictions, the rest of the season’s busiest days are still on the horizon, with the peak expected to fall in the final few days leading up to Christmas. With this year’s holiday falling on a Thursday for the first time in over a decade, retailers may see a more sustained high-traffic period in the week preceding Dec. 25.

“This weekend truly marks the kickoff to a successful holiday season for retailers, and beyond that, a successful 2026 as well,” continued Gustafson. “According to ShopperTrak Analytics, in 2024, 77% of the retailers who outperformed in shopper traffic during the holiday season, continued to outperform into the first half of 2025. The momentum and loyalty gained by providing great shopping experiences this weekend can help retailers into the new year.”

To get more holiday insights from Sensormatic Solutions, visit www.sensormatic.com. To make sure you’re up-to-date on all things holiday retail, use #SensormaticHolidays to follow along on LinkedIn and X.

About Johnson Controls

At Johnson Controls (NYSE:JCI), we transform the environments where people live, work, learn and play. As the global leader in smart, healthy and sustainable buildings, our mission is to reimagine the performance of buildings to serve people, places and the planet.

Building on a proud history of 140 years of innovation, we deliver the blueprint of the future for industries such as healthcare, schools, data centers, airports, stadiums, manufacturing and beyond through OpenBlue, our comprehensive digital offering.

Today, Johnson Controls offers the world’s largest portfolio of building technology and software as well as service solutions from some of the most trusted names in the industry.

Visit www.johnsoncontrols.com for more information and follow @johnsoncontrols on social platforms.

About Sensormatic Solutions

Sensormatic Solutions, the leading global retail solutions portfolio of Johnson Controls, powers safe, secure and seamless retail experiences. For more than 50 years, the brand has been at the forefront of the industry’s fast-moving technology adoption, redefining retail operations on a global scale and turning insights into actions. Sensormatic Solutions delivers an interconnected ecosystem of loss prevention, inventory intelligence and traffic insight solutions, along with our services and partners to enable retailers worldwide to innovate and elevate with precision, connecting data-driven outcomes that shape retail’s future. Please visit Sensormatic Solutions or follow us on LinkedIn, X and our YouTube channel. Please visit Sensormatic Solutions or follow us on LinkedIn, X and our YouTube channel.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251129908975/en/

Media Contacts:

Jaclyn Messina

Sensormatic Solutions by Johnson Controls

Work: +1-561-235-6458

Email: [email protected]

Madison Southall

Sensormatic Solutions by Johnson Controls

Work: +1-215-869-6452

Email: [email protected]

Grace Torrance

Matter on behalf of Sensormatic Solutions

Work: +1-978-518-4504

Email: [email protected]

KEYWORDS: Switzerland Europe

INDUSTRY KEYWORDS: Consulting Luxury Professional Services Discount/Variety Specialty Department Stores Marketing Communications Fashion Retail Data Analytics

MEDIA:

Logo

Posted on November 29, 2025 12:26 pm
Mastercard SpendingPulse: U.S. Black Friday Retail Sales Up +4.1% YOY as Holiday Momentum Builds

Mastercard SpendingPulse: U.S. Black Friday Retail Sales Up +4.1% YOY as Holiday Momentum Builds

Consumers scour for big deals and promotions, especially online as e-commerce sales grew +10.4% compared to 2024

PURCHASE, N.Y.–(BUSINESS WIRE)–
According to preliminary insights from Mastercard SpendingPulse™,U.S. retail sales excluding autos were up +4.1% on Black Friday, November 28 compared to Black Friday 2024. Mastercard SpendingPulse measures in-store and online retail sales, representing all payment types, and is not adjusted for inflation.

This year’s Black Friday tells a story of comfort, connection, and savvy shopping as consumers prepare for meaningful moments with family and friends. Spending growth on apparel was particularly strong both online and in-store, suggesting shoppers refreshed wardrobes while leaning into value-driven choices and convenience.

“Consumers are showing incredible savviness this season. They’re navigating an uncertain environment by shopping early, leveraging promotions, and investing in wish-list items,” said Michelle Meyer, chief economist at the Mastercard Economics Institute.

Compared to Black Friday last year, spending growth trends by category include:

Bundled-up style and sparkle: Apparel climbed +5.7% (online +6.1%, in-store +5.4%), as chilly temperatures and seasonal deals encouraged spending on new fashions. Jewelry also rose +2.75% (online +4.2%), as consumers opted for gifts that shine.

Sleighing online shopping: E-commerce retail sales ex-autos jumped +10.4%, as shoppers increasingly value speed and convenience. In-store sales grew more modestly (+1.7%) but remain essential to consumers for tactile experiences.

Festive feasts: Restaurants grew +4.5%, as dining out has become part of the holiday ritual to celebrate the season and underscores consumers’ continued desire for experiences.

Across the map: Spending outperformed in pockets of the country including New England, the Midwest and Southeast. Overall sales in New England and the Midwest were boosted by Apparel, as spending on cold-weather gear was likely supported by the drop in temperatures. The Southeast has shown persistent strength this year.

As part of Mastercard’s 2030 commitment to advancing inclusive, secure, and frictionless commerce, this year’s surge in online shopping showcases how technology is transforming the way consumers pay. Shoppers are enjoying seamless checkout experiences across devices, from smartphones to connected home assistants, making holiday shopping faster, safer, and more intuitive than ever before.

As online sales soar, so do opportunities for fraud. Mastercard research shows that 72% of consumers shop on unfamiliar websites, even though one in four claim to avoid them. The biggest red flags? Prices that seem too good to be true (52%), poor spelling or grammar (48%), and requests for unnecessary personal information (49%). Unfortunately, nearly 1 in 5 shoppers have had items that never arrived, and 16% have received counterfeit goods in past seasons.

Mastercard encourages consumers to shop smart by sticking to trusted retailers and using secure payment methods. If you suspect suspicious activity or encounter a scam, report it immediately to your bank or card provider. These steps, combined with Mastercard’s advanced fraud prevention tools, help ensure holiday shopping remains joyful and safe.

About Mastercard SpendingPulse

Mastercard SpendingPulse measures national retail sales based on aggregated and anonymized Mastercard insights, representing all payment types in select markets around the world.

Mastercard SpendingPulse defines “U.S. retail sales” as sales at retailers and food services merchants of all sizes. Sales activity within most of the services sector (for example, travel services such as airlines and lodging) are not included in the total retail sales figure. SpendingPulse insights are not indicative of Mastercard company performance; insights and forecast are subject to change.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251129379791/en/

Laura Nizlek | [email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Home Goods Retail Security Technology Other Consumer Online Retail Luxury Other Retail Electronic Commerce Department Stores Restaurant/Bar Specialty Payments Consumer Jewelry Fashion

MEDIA:

Logo

Posted on November 29, 2025 10:43 am
Class Action Announcement STUB: A Securities Fraud Class Action Lawsuit Was Filed Against StubHub Holdings, Inc. (STUB)

PR Newswire

RADNOR, Pa.
, Nov. 29, 2025 /PRNewswire/ — The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against StubHub Holdings, Inc. (“StubHub”) (NYSE: STUB) on behalf of those who purchased or otherwise acquired StubHub common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Offering Documents”) issued in connection with StubHub’s September 2025 initial public offering. The lead plaintiff deadline is January 23, 2026.

CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:

If you suffered StubHub losses, you mayCLICK HERE or copy and paste the following link into your browser: https://www.ktmc.com/new-cases/stubhub-holdings-inc?utm_source=PR_Newswire&mktm=PR

You can also contact attorney

Jonathan Naji, Esq.

by calling (484) 270-1453 or by email at [email protected].

DEFENDANTS’ ALLEGED MISCONDUCT:

The complaint alleges that, in the Offering Documents, Defendants made false and/or misleading statements and/or failed to disclose that: (1) StubHub was experiencing changes in the timing of payments to vendors; (2) those changes had a significant adverse impact on StubHub’s free cash flow, including trailing 12 months free cash flow; (3) as a result, StubHub’s free cash flow reports were materially misleading; and (4) that, as a result of the foregoing, Defendants’ positive statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

THE LEAD PLAINTIFF PROCESS:

StubHub investors may, no later than January 23, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check, LLP
encourages StubHub investors who have suffered significant losses to contact the firm directly to acquire more information.

CLICK HERE
TO SIGN UP FOR THE CASE
OR GO TO:
https://www.ktmc.com/new-cases/stubhub-holdings-inc?utm_source=PR_Newswire&mktm=PR

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.

CONTACT:
Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected]

May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/class-action-announcement-stub-a-securities-fraud-class-action-lawsuit-was-filed-against-stubhub-holdings-inc-stub-302627145.html

SOURCE Kessler Topaz Meltzer & Check, LLP

Posts pagination

Page 1 Page 2 … Page 38,509 Next page